αAllAboutAminos
Subscribe
≡
Weight regain now has a timetable — and a Nature mouse study tests the limits of semaglutide enthusiasm
Read the Sunday Brief →
Neuromodulatory peptide · 9 aa

DSIP

Delta sleep-inducing peptide, a nonapeptide neuromodulator

Delta Sleep-Inducing Peptide (DSIP) is an endogenous nonapeptide first isolated in the 1970s from the cerebral venous blood of rabbits during induced slow-wave sleep. It is classified as a neuromodulator and has been studied for its possible roles in sleep regulation, stress-axis modulation, and pain perception. Despite its name, DSIP's actual influence on sleep architecture in humans remains uncertain and inconsistently reproduced across studies. It is not an approved drug and is used only in research and community self-experimentation contexts.

Studies tracked
1
This page is editorial content summarising reported literature. It does not constitute medical advice and should not be used to guide treatment decisions. Nothing on this page states that any substance cures, treats, or prevents any condition.
Safety first

Side effects & risks

The safety profile of DSIP is poorly characterized because human data is sparse, dated, and small in scale. In the limited studies conducted, DSIP was often described as relatively well tolerated at the doses tested, but this does not establish long-term or real-world safety. Reported or theoretically possible effects include headache, transient dizziness, fatigue or grogginess, and injection-site reactions with subcutaneous use. Because DSIP may interact with the stress axis and multiple neurotransmitter systems, effects on mood, hormones, and sleep architecture cannot be ruled out and are not well studied. The purity and identity of research-grade or gray-market peptide products is not guaranteed, which introduces additional and unpredictable risk. There is no established data on interactions with medications, on use during pregnancy or breastfeeding, or on chronic exposure. Anyone considering DSIP should consult a qualified clinician first, particularly if they have existing health conditions or take other medications. Given the thin evidence, the honest position is that many potential risks remain simply unknown.

02

Latest studies

Study · DSIPWeak / none

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, examines a broad class of research compounds called therapeutic peptides and asks whether they might have a role in orthopaedic medicine — including bone, tendon, muscle, and nerve recovery. Researchers reviewed the published scientific literature on several peptides, including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon. Each compound was evaluated for its proposed biological mechanism and its relevance to orthopaedic injury and recovery. The review found that these peptides appear to act on molecular pathways involved in tissue repair, inflammation resolution, and nerve signalling. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu were reported to promote blood vessel formation and tissue remodelling. Growth hormone-stimulating peptides like ipamorelin, CJC-1295, tesamorelin, and sermorelin were described as activating repair-related growth signals. Peptides such as epitalon were linked to cellular energy regulation, and neuroactive peptides like semax and selank were associated with nerve growth factor pathways. However, the authors explicitly noted that clinical trials in human orthopaedic patients are currently lacking. The mechanistic evidence reviewed comes primarily from laboratory and animal studies. No adverse event data specific to this review were reported in the...

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsn=——January 1, 2026
03

Community discussion

4 community discussions

Community-reported · not verified

These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.

r/Biohacking · Aug 3neutral

“Looking for experiences with SS-31, MOTS-C, DSIP& Epitalon.”

A user solicits firsthand experiences with SS-31, MOTS-C, DSIP, and epitalon, a cluster commonly grouped under mitochondrial and longevity interests. Replies compare perceived energy and sleep effects, discuss cycling versus continuous use, and note that the human evidence for each is limited and largely early-stage.

Protocol Discussion
04

Reported protocols (with caveats)

⚠ Editor's caveat
These dose ranges describe what people are reported to do, not what is established as safe or effective. There is no FDA-approved indication. Self-injection of unscheduled peptides carries known and unknown risks. Talk to a clinician.

The following describes reported research and community use only and is not a recommendation. In community and self-experimentation contexts, DSIP is typically reported as a subcutaneous injection, with anecdotal doses commonly described in the range of roughly 100-300 micrograms, sometimes taken in the evening before intended sleep. Some users report intranasal use, though injectable forms are more frequently discussed. Reported timing centers on administration shortly before bedtime, reflecting its purported sleep association. There is no established or validated dosing protocol, and the older clinical literature used varied routes and amounts under research conditions. All such use falls under research-use-only framing, and reported protocols reflect unverified anecdote rather than clinical guidance.